|Day Low/High||108.22 / 110.10|
|52 Wk Low/High||104.17 / 132.13|
I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure. In other words, I am sticking to my script...
Slow day, at meetings all morning. Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing. I reflected on my July call that we have hit a Genera...
For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.
Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.
Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.
Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
It may be time to embrace the contrary. First issue (!!): The Palm Beach Chronicles. My weekly (brief) technical review of the markets -- cooling off ahead? BTIG's Stockton is bullish and so, as I have expressed, are most others! Campbell ...
'Milestone payments' could boost deal's $125 million announced price.
The worst appears to be over for this sector; we could see big growth ahead.
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.
These 'wing and a prayer' stocks are full of surprises.
It will likely take several months of base building before LLY looks better on the charts.
U.S. stocks pulled back Wednesday, from their record highs on Tuesday, when the Dow Jones Industrial Average crossed 19,000 and the S&P 500 topped 2,200.
Here are two extremes. Eli Lilly down nearly $12, or more than 15%, in pre-market trading on the failure of Solanezumab to meet its primary endpoint. And Deere up $9, or more than 10%, in the pre-market on a giant earnings beat.
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
Stocks in the health care sector seem to have no underpinnings whatsoever.
Today there was a virtual vacuum of good news in the stock market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
A chart buyer will actually wait for the trend to turn before buying.
Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...
A class-action lawsuit over poultry pricing could result in substantial damages for Tyson Foods, analyst says.
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.